D&P Bioinnovations [D&P] first therapeutic application is to regenerate a damaged esophagus (organ providing food to the stomach) with its developed medical device implant. However, D&P’s device can serve as a platform tech for other indications such as regenerating damaged blood vessels, nerves, muscle, tendons/ligaments, and gastro-intestine. The technology development has been tested in 6 different diseased animal models and has the potential to impact the global regenerative medicine market that is expected to accrue > $200B by the late 2020s.
Dr. DEREK C. DASHTI
Dr. Derek C. Dashti
(BS, MS – Bioengineering;
PhD – Bioinnovation/Regenerative Medicine;
Executive MBA – Focused specializations: Healthcare, Digital Transformation, Innovation & Entrepreneurship)
Dr. Dashti holds over 16 years of stem cell tissue engineering and regenerative medicine research experience. He is a doctoral NSF Fellow as well as a National University Innovation Fellow and has received core training of translating biomedical academic research from “benchside” to “bedside.”
We are developing an implantable, bioresorbable medical device to functionally regenerate a damaged esophagus within the body. Our device will treat those suffering from severe GERD/ advanced Barrett’s Esophagus (chronic regurgitation of stomach acid), esophageal cancer and in pediatrics where birth defects of the esophagus and poisonous ingestions are fatal addressing the $20 billion U.S. annual market. Our product improves the standard of care by avoiding surgical reconstruction from the stomach (gastric pull up) and saves over $240,000 per treatment as compared to the standard.